Figure 2.
Outcome according to CRMRDstatus in older AML patients treated with low-intensive therapy or hypomethylating agents. RFS (A) and OS (B) of patients in CR/CRi according to persistence (ie, ≥0.01%) vs undetectable (ie, <0.01%) MRD after induction. (C) Patients with undetectable MRD are listed according to their outcome: OS is depicted by gray bars, whereas progression and deaths are identified by orange and purple boxes, respectively. P values were determined by the 2-sided log-rank test.

Outcome according to CRMRDstatus in older AML patients treated with low-intensive therapy or hypomethylating agents. RFS (A) and OS (B) of patients in CR/CRi according to persistence (ie, ≥0.01%) vs undetectable (ie, <0.01%) MRD after induction. (C) Patients with undetectable MRD are listed according to their outcome: OS is depicted by gray bars, whereas progression and deaths are identified by orange and purple boxes, respectively. P values were determined by the 2-sided log-rank test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal